RE:New Press Release - ProMIS Neurosciences Issues Letter to ShareholdersAt least he acknowledged two repeat concerns.
"... our tight control on cash management."
"Our priorities are clear: to advance PMN310 through clinical development; to increase the Company’s visibility..."